| Abstrakt: |
In the phase 2 BrigHTN trial, 248 patients with treatment-resistant hypertension on stable doses of ≥3 antihypertensive agents including a diuretic were randomised to receive the selective aldosterone synthase inhibitor baxdrostat 0.5mg, 1mg or 2mg or placebo once daily for 12 weeks. There were dose-dependent changes in the primary endpoint of change in systolic BP from baseline to week 12 with baxdrostat 0.5mg, 1mg and 2mg of -12.1, -17.5 and -20.3mm Hg, respectively, compared with -9.4mm Hg with placebo; the placebo-adjusted decrease in mean systolic BP at week 12 was -11.0mm Hg with baxdrostat 2mg (p<0.001) and -8.1mm Hg with baxdrostat 1mg (p=0.003). [ABSTRACT FROM AUTHOR] |
